INVESTORS
09/05/2022: eureKING_Prospectus
09/05/2022: eureKING Launch Press Release_English
09/05/2022: eureKING Launch Press Release_Annex_French
10/05/2022: eureKING Results Press Release_English
30/12/2022: Interim Financial Report For The Six-Month Period Ended September 30, 2022
30/12/2022: Press Release on Interim Financial Report HY 2022 EN
28/04/2023:Financial Report for the Period Ending December 31st, 2022
28/04/2023: Press Release on Financial Report FY 2022 EN
16/05/2023: Press Release on Intention to Combine with Skyepharma to Build a New European Bio-CDMO leader
30/05/2023: Press Release on eureKING Skyepharma Put Option Announcement
30/06/2023: eureKING Combined General Meeting of June 30, 2023 – Voting results
30/06/2023: eureKING Special General Meeting of market shareholders of June 30, 2023 – Voting results
07/07/2023:
All documents relating to the 2023 Annual General Meeting can be found here.
08/08/2023: Press Release – eureKING and Skyepharma revise the terms of their business combination
11/08/2023: eureKING Presentation
11/08/2023: Press Release – eureKING AGE and Special meetings
21/08/2023: Press Release – Notice of Redemption
01/09/2023: Press Release – Proposed IBC with Skyepharma and Proposed Acquisition of SCTbio
Related documents:
04/09/2023: SCTbio’s statutory unaudited Czech GAAP financial statements for the fiscal year ended December 31, 2022
04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2022 et Rapport d’audit
04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2021 et rapport d’audit
04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2020 et rapport d’audit
17/09/2023: eureKING – Publication site internet sur conventions réglementées 2023
21/09/2023: eureKING Press release – Interim financial report 2023
21/09/2023: Interim Financial Report for the six-month period ended June 30, 2023
22/09/2023: Press Release – Results of the redemption requests of eureKING’s Market Shares